In this article (Clin Cancer Res 2010;16:3670–83), which was published in the July 15, 2010 issue of Clinical Cancer Research (1), there was an error in Fig. 1 in that activating PIK3CA mutations in JIMT-1 (C420R) and MFM-223 (H1047R) were not reported. The corrected figure and legend appear here. Based on revised statistical analysis, the second sentence of the second paragraph of the Results section should read, “We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without any PI3K pathway-activating biomarker (P = 0.01 PIK3CA vs. wild-type, P = 0.02 HER2 vs. wild-type, Mann–Whitney U test; Fig. 1C).” This finding does not impact the overall conclusions of the article regarding the predictive value of PIK3CA mutations in preclinical breast cancer models. We apologize to the readers for any inconvenience this omission may have caused.

1.
O'Brien
C
,
Wallin
JJ
,
Sampath
D
,
GuhaThakurta
D
,
Savage
H
,
Punnoose
EA
, et al
Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models
Clin Cancer Res
2010
;
16
:
3670
83
.